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Abstract Asthma drugs are amongst the most frequently
used drugs in childhood, but international comparisons
on type and indication of use are lacking. The aim of this
study was to describe asthma drug use in children with and
without asthma in the Netherlands (NL), Italy (IT), and
the United Kingdom (UK). We conducted a retrospective
analysis of outpatient medical records of children 0–
18 years from 1 January 2000 until 31 December 2005.
For all children, prescription rates of asthma drugs were
studied by country, age, asthma diagnosis, and off-label
What is already known
⋅ Asthma drugs are among the most prescribed drugs to children
⋅ Most frequently used asthma drugs are short-acting beta2-mimetics
and inhaled steroids
⋅ There is a large variability in prescription rates between countries
What this study adds
⋅ Off-label use of asthma drugs in children is low
⋅ Linking multi-country databases makes it possible to study country
specific pediatric drug use in a systematic manner without being
hampered by methodological differences
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status. One-year prevalence rates were calculated per 100
children per patient-year (PY). The cohort consisted of
671,831 children of whom 49,442 had been diagnosed with
asthma at any time during follow-up. ß2-mimetics and
inhaled steroids were the most frequently prescribed asthma
drug classes in NL (4.9 and 4.1/100 PY), the UK (8.7 and
5.3/100 PY) and IT (7.2 and 16.2/100 PY), respectively.
Xanthines, anticholinergics, leukotriene receptor antagonists,
and anti-allergics were prescribed in less than one child per
100 per year. In patients without asthma, ß2-mimetics were
used most frequently. Country differences were highest for
steroids, (Italy highest), and for ß2-mimetics (the UK highest).
Off-label use was low, and most pronounced for ß2-mimetics
in children <18 months (IT) and combined ß2-mimetics+
anticholinergics in children <6 years (NL). Conclusion: This
study shows that among all asthma drugs, ß2-mimetics and
inhaled steroids are most often used, also in children without
asthma, and with large variability between countries. Linking
multi-country databases allows us to study country specific
pediatric drug use in a systematic manner without being
hampered by methodological differences. This study under-
lines the potency of healthcare databases in rapidly providing
data on pediatric drug use and possibly safety.
Keywords Pediatric asthma . Drug utilization
Introduction
Respiratory drugs are amongst the most frequently pre-
scribed drugs in children, and especially, asthma drugs are
frequently prescribed [32]. Prevalence rates of asthma drug
use range between 4% and 26%, depending on country, age
range, and study period (Table 1) [2, 6, 9, 11, 12, 14, 16,
18, 20, 21, 40, 43]. Asthma is defined as a chronic
inflammatory disorder of the airways and is associated
with airway hyperresponsiveness that leads to recurrent
episodes of wheezing, breathlessness, chest tightness, and
coughing [35]. In children aged 5 years and younger, the
clinical symptoms of asthma are variable and non-specific.
Furthermore, routine testing for main asthma features is not
possible in this age group, which hampers making a
diagnosis.
According to the Global Initiative for Asthma (GINA),
bronchodilators, (inhaled short-acting ß2-mimetics, SABA;
long-acting ß2-mimetics, LABA; anticholinergics, ACH),
inhaled corticosteroids (ICS), and alternative (add-on)
treatments such as leukotriene receptor antagonists (LTRA),
xanthines and anti-allergics (cromones) all have a place in
the treatment of childhood asthma, although at various
stages depending on severity of illness [35]. In pediatrics,
asthma is one of the main indications for which these drugs
are used.
Apart from these respiratory drugs, systemic glucocorti-
coids are also used in the treatment of asthma. However, due
to side effects such as potential adrenal suppression and
growth impairment with long-term use [33, 35], use of
systemic glucocorticoids in asthmatic children is restricted to
asthma exacerbations and very severe persistent asthma [35].
Use of asthma drugs varies largely between countries as
observed from the literature (Table 1). Part of this variability
may be explained by differences in age distribution and type
of data (i.e., surveys, prescriptions, dispensing), which
hampers good comparisons between studies. To better
explore differences in prescription rates of asthma drug use
between countries, we conducted a retrospective cohort
study in three European countries: the Netherlands, Italy,
and UK, using the same methodology and stratifying by age,
sex, and asthma diagnosis.
Methods
Data collection
Data were obtained from general practice medical record
databases in three countries according to a common protocol.
Databases were the Pedianet database in Italy [25], the
Integrated Primary Care Information (IPCI) database in the
Netherlands [39], and the Mediplus Disease Analyzer-
Mediplus database (IMS-DA) in the UK [42]. Details are
described elsewhere [32]. Primary care in children is
provided by the general practitioner (GP) in the UK and
the Netherlands, and by a family pediatrician in Italy. These
primary care medical record databases were chosen because
they contain detailed information on the population, diagnoses,
and prescriptions. The geographic location of the databases
allowed us to study North and South European differences in
drug prescribing.
Study population
The study population consisted of all children aged 0–
18 years (0–11 years in Italy) during the study period 1
January 2000 until 31 December 2005 (1 January 2001
until 31 December 2005 for Italy).All persons needed to
have a database history of ≥6 months, except for children
born during the study period. For each child, the person-
years of follow-up were calculated, stratified by calendar
year, age group, sex, and asthma diagnosis. For privacy
issues, some databases only contain the year of birth,
therefore age was assessed at the 1st of January of each
year, and in order to identify infants, preschoolers, and
adolescents separately. We used modified the International
Conference of Harmonization age categories to stratify by
age (<2, ≥2–≤4, 5–11, and ≥12 years of age) [17]. Each
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child was followed from the start of the study until the
patient left practice or end of the study period (whichever
was earliest).
Assessment of asthma
For each child, we assessed whether a diagnosis of asthma
was made at anytime in its medical records using the
following diagnostic codes: ICPC code R96 in IPCI,
International Classification of Diseases (ICD)-9 code 493
in Pedianet and ICD-10 code J45 in IMS and free text [22,
36, 37]. If at any time during the follow-up asthma was
diagnosed, the child was considered asthmatic for the entire
period.
Classification of prescriptions
Drug prescriptions were categorized based on the World
Health Organization's Anatomical Therapeutic Chemical
(ATC) classification system [41]. All prescriptions for
“obstructive airway diseases” (ATC R03) and “glucocorti-
costeroids for systemic use” (ATC H02AB) were obtained
from the prescription files and further categorized into:
ß2-mimetics (either short-acting [SABA] or long-acting
[LABA]), inhalation glucocorticosteroids, inhalation anti-
cholinergics, fixed combination of SABA+short-acting
anticholinergics, fixed combination of LABA+inhalation
glucocorticosteroids, anti-allergic agents (best known as
cromones), xanthines, and leukotriene receptor antagonists.
Use of ß2-mimetics+ICS was classified as a non-fixed
combination if the child used ß2-mimetics and an ICS in
the same year. For each drug class, we calculated prevalence
rates for the most frequently prescribed drugs (top three) by
country.
Due to differences in labeling status between countries,
off-label use was assessed per country. A drug was
classified as being “off-label” if the child receiving the
prescription had an age below the minimum age as specified
in the summary product characteristics (SPC) or the drug was
given for a different indication than specified in the SPC. This
is in line with the new definition of pediatric off-label use
provided by the Task Force in Europe for Drug development
for Young [26].
Statistical analysis
Annual prevalence rates (per 1,000 PY or per 100 PY) of
asthma drug use were calculated by counting the number of
children using each drug or drug class by calendar year,
age, sex, asthma status, and country and dividing this
number by the number of person-years attributed by the
different strata. User prevalence rates can be interpreted as
the number of children per 1,000 children that uses a
specific drug (class) during 1 year. If expressed per 100 PY
it can be freely translated as the percentage of children
using these drugs in 1 year. The fact that we used annual
prevalence rates means that a child who uses one drug
(class) multiple times in 1 year, will be counted only once
for that year. The use of person-years rather than persons in
the denominator was necessary due to the dynamic nature
of the cohort where persons could have variables durations
of follow-up.
Differences in prescription rates between countries were
tested by means of the X2-test.
Results
Patient characteristics
Our population consisted of 671,831 children (66% UK,
19% IT, 15% NL) of whom 49,442 (7.4%) had asthma at
any point during follow-up (Table 2).
Asthma drug classes
The user prevalence rate of any asthma drug was highest in
young children and decreased with age (Figs. 1 and 2), it
was highest in Italy for each age category. The difference
between NL, the UK, and IT is largest for the youngest age
categories with user prevalence rates of 25–30/100 PY in
Italy, rates of 12 in the UK, and 10/100 PY in NL (Figs. 3
and 4). In the youngest age groups, prescription rates were
higher for boys. This pattern switched in adolescence
(between the ages 14 to 16), where user prevalence rates
for almost all drug classes were higher in girls (Fig. 1).
ß2-mimetics and ICS were each used by one to ten
children per 100 PY in all age categories in each country
(Fig. 2). In Italy, prevalence of use of ICS was higher
than use of ß2-mimetics and even exceeded 10/100 PY in
the youngest age group. The fixed combinations of
anticholinergics+SABA were frequently used in the
Netherlands and Italy but not in the UK, where mostly
anticholinergics were used as single compound. Leuko-
triene receptor antagonists, anti-allergics, and xanthines
were used by less than one child per 100 PY in each
country and each age category, which is in concordance
with protocols concerning asthma treatment. Fixed com-
binations of ICS+LABA were infrequently used in young
children but exceeded 1/100 PY in adolescents in the
Netherlands. Systemic use of steroids was very heteroge-
neous between countries. User rates exceeding 10/100 PY
were observed in Italy, especially in the youngest
children, whereas user rates were five- to eightfolds
lower in the UK and almost 20-fold lower in the
Netherlands.
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User prevalence rates for individual drugs
The prevalence of SABA use in children with asthma was
similar in the Netherlands and Italy but much higher in the
UK (30 vs. 60/100 PY). In children without asthma diagnosis,
the prevalence was between one and eight per 100 PY. The
most frequently prescribed SABAs were salbutamol and
terbutaline in NL and the UK, whereas terbutaline was not
frequently used in Italy (Table 3). User rates of LABA (this
can be combined or single use) were very low (<1/100 PY),
but strongly increased with age in children with asthma.
Most frequently used drugs were salmeterol and formoterol.
In children without asthma, use of LABA was negligible
(Table 3 and Fig. 3). Single use of ß2-mimetics (without a
prescription for ICS in the same year) was highest in the UK
(195/1,000 PY in children with asthma and 23 in children
without). In NL and IT prevalence rates were 127 and 75/
1000 PY in children with asthma and 12 and 18/1000 PY in
children without an asthma diagnosis. In both countries
prevalence rates decreased gradually with increasing age.
ICS were most frequently prescribed in Italy, especially
in children <2 years of age. In children with asthma, ICS
use was highest in the UK. The choice of drug differed;
fluticasone was most often prescribed in NL and beclome-
thasone in the UK and Italy. Among the children with
asthma who used ß2-mimetics, 42% were not prescribed
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asthma drugs (all ATC R03)
Table 2 Population size by country, age, sex, and asthma diagnosis
Patient
characteristics
NL Italya UK Total
Children with
asthma
Total
population
Children with
asthma
Total
population
Children with
asthma
Total
population
Children with
asthma
No.b (% of total) No.b (% of total) No.b (% of total) No.b (% of total)
Age
<2 years 2,165 (8.4) 25,694 2,539 (4.6) 54,999 2,977 (3.8) 79,246 7,681 (5.7)
≥2–≤4 years 2,820 (11.8) 23,902 4,269 (7.3) 58,735 7,610 (7.5) 101,835 14,699 (8.0)
5–≤11 years 5,545 (11.7) 47,435 5,399 (7.5) 72,264 19,856 (12.8) 155,488 30,800 (11.2)
12–≤18 years 3,689 (8.3) 44,636 19,809 (13.3) 149,093 23,498 (12.1)
Sex
Females 3,940 (7.9) 49,709 2,851 (4.7) 60,089 14,377 (6.5) 219,669 21,167 (6.4)
Males 5,419 (10.5) 51,850 4,730 (7.2) 65,361 18,125 (8.1) 225,153 28,274 (8.3)
Total 9,359 (9.2) 101,559 7,581 (6.0) 125,450 32,502 (7.9) 444,822 49,442 (7.4)
PY person-years
a For Italy the age range included only 0–11 years for the years 2001–2005
b The number of children in the various age groups does not add up to the total since one child can contribute to more than one age category during the
study period
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ICS in that year in NL, 26% in Italy, and 33% in the UK. In
children without asthma, ICS use was low in NL and the
UK but reached rates of more than 10/100 PY in Italy.
Oral corticosteroid use was highest in Italy, with
prescription rates of 26/100 PY in children with asthma
and 7/100 PY in children without asthma. Rates were
especially high in the younger age categories. In the other
countries, prescription rates in children with asthma were
much lower in each age category, both in children with and
without asthma. The most frequently prescribed drugs were
betamethasone in Italy and prednisolone in NL and the UK.
Combination preparations
Use of the fixed combinations of short-acting SABA+ACH
was low overall, but most frequent in Italy. Prescription
rates decreased with age.
For the fixed combinations of ICS+LABA, use was
highest in NL with six per 100 PY in children with asthma.
A clear increase of prescription rates with age was seen in
all three countries.
Use of the loose combination of ß2-mimetics+ICS was
highest in IT (55/1,000 PY), followed by the UK (48/
1,000 PY) and NL (24/1,000 PY). In children with asthma
prevalence rates were highest in the UK (404/1,000 PY),
followed by IT (217) and NL (177)
Off-label use
Off-label use defined by use below the minimum age as
specified in the SPC was investigated in Italy and NL. In
Italy, salbutamol is indicated for use in children from the
age of 18 months onwards, however user rates were 22.7/
100 PY in children with asthma and 7.5 in children without
asthma diagnosis below 18 months. In NL, off-label use
was observed for the fixed combinations of ß2-mimetics+
anticholinergics. The minimum age for use of these drugs is
6 years in NL, however, prescription rates in children <6 years
were 0.5–3.5/100 PY in NL (data not shown).
Off-label use defined as use for other indications than
specified in the SPC (for drugs that only had asthma or
COPD as indication) in children without recorded asthma
diagnosis was observed in all three countries for several
drugs (Table 4). In Italy, budesonide had the highest off-
label prescription rate; in NL, salbutamol; and in the UK,
beclomathesone.
Discussion
This paper provides detailed information on asthma drug
use in three European countries, and clearly demonstrates
the similarities and differences in prescription rates.
NL: the Netherlands, IT: Italy, UK: the United Kingdom, b2-mim= ß2-mimetics; ics=inhalation corticosteroids; ach=anticholinergics;
saba+ach= fixed combination of short-acting ß2-mimetics+anticholinergics; laba+ics= fixed combination of long-acting ß2-
mimetics+inhalation corticosteroids; scort=systemic corticosteroids
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Whereas short-acting ß2-mimetics are the most frequently
used drugs for treatment of asthma in the Netherlands and the
UK, inhaled and systemic corticosteroids are most frequently
used in Italy, especially in the youngest age groups. Long-
acting products, anticholinergics, xanthines, and LTRAswere,
in general, infrequently prescribed in all countries.
Our data are in line with previous studies on asthma drug
use in children, which also demonstrated that short-acting
ß2-mimetics and inhaled corticosteroids were prescribed
most, but these studies often considered only one country or a
region [14, 15], whereas our study captures multiple countries
in different European regions. Our data also confirm findings
of a recent survey showing high use of inhaled ß2-mimetics
in northern Europe and high usage of corticosteroids in
southern Europe [4]. The north south gradient that we
observed in the prescription of asthma drugs cannot be
explained by country specific differences in asthma treatment
protocols, as the protocols in the Netherlands; the UK and
Italy are all based on the GINA guidelines.
There are various prescribing behaviors which deserve
specific attention since they may be associated with a
differential risk of adverse drug reactions. First of all,
Table 3 Prevalence of respiratory drug use per country by treatment class and asthma diagnosis
Netherlands Italy UK
Asthma No asthma Asthma No asthma Asthma No asthma
SABA
Salbutamol 276 19 Salbutamol 283 59 Salbutamol 519 32
Terbutaline 39 2 Terbutaline 1.4 0.1 Terbutaline 88 2.8
Overall 293 17 284 59 596 35
LABA
Salmeterol 14 0.4 Salmeterol 13 0.5 Salmeterol 40 0.6
Formoterol 7.6 0.2 Formoterol 1.6 0.1 Formoterol 2.5 0.02
Overall 21 0.6 15 0.6 42 0.6
ICS
Fluticasone 162 8 Beclomethasone 239 98 Beclomethasone 313 11
Budesonide 68 4 Fluticasone 122 10 Budesonide 72 1.9
Beclomethasone 50 2 Flunisolide 76 32 Fluticasone 63 1.5
Overall 271 14 404 143 437 14
LTRA
Montelukast 5.5 0.1 Montelukast 37 1.7 Montelukast 15 0.3
Zafirlukast 0.0 0.0 Zafirlukast 0.2 0.02
Overall 5.5 0.1 38 1.7 15 0.3
Short-acting anticholinergics
Ipratropium bromide 15.7 1.6 Ipratropium 6.2 2.4 Ipratropium 9.1 2.7
Oxitropium 0.3 0.1 Oxitropium 0.04 0
Overall 16 1.6 6.4 2.5 9.1 2.7
ß2-agonists+ICS (non-fixed)*
177 5 217 42 404 12
SABA+SACH (fixed)
Fenoterol+Ipratropium 19 4.1 Salbutamol+Ipratropium 104 25 Salbutamol+Ipratropium 0.7 0.06
Salbutamol+Ipratropium 0.9 0.9 Fenoterol+Ipratropium 0.1 0.0 Fenoterol+Ipratropium 0.05 0
Overall 20 4.4 104 25 0.07 0
LABA+ICS (fixed)
Salmeterol+Fluticasone 33 1.3 Salmeterol+Fluticasone 37 1.3 Salmeterol+Fluticasone 31 0.5
Formoterol+Budesonide 6.8 0.3 Formoterol+Budesonide 2.1 0.1 Formoterol+Budesonide 6.1 0.07
Overall 60 2.3 38 1.4 37 0.6
Asthma prevalence in children with asthma, no asthma prevalence in children without asthma, SABA short-acting ß2-mimetics, LABA long-acting
ß2-mimetics, ICS inhalation corticosteroids, LTRA leukotriene receptor antagonists, ß2-agonists+ICS (non-fixed) non-fixed combination of
ß2-mimetics+inhalation corticosteroids, SABA+SACH (fixed) fixed combination of short-acting ß2-mimetics+short-acting anticholinergics,
LABA+ICS (fixed) fixed combination of long-acting ß2-mimetics+inhalation corticosteroids
*Could either be the combination of LABA+ICS 1or SABA+ICS but always a loose combination (more than one device)
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SABA use is high in the lower age categories which may
at least partly be explained by the fact that they are
recommended on an as-needed basis for acute wheezing in
preschool children [7]. However, paradoxical responses like
deterioration of asthma with use of these drugs have been
reported in infants [34].
Secondly, prescription rates for long-acting ß2-mimetics
were low for all three countries, which is in line with guidelines
and recommendable since a black box warning was issued by
the FDA due to safety issues in children, especially in mono-
use [13]. Thirdly, in children with asthma, the percentage of
children using β2-mimetics without ICS as controller was
substantial, especially in the UK and Netherlands. A possible
explanation could be that these children were intermittently
treated with SABAs on an as-needed basis as defined in
the first step of the guidelines [35]. However, chronic use of
ß2-mimetics without ICS is contraindicated in children with
asthma because it may lead to increased airway inflammation
and worsening of asthma control, and is in severe cases even
associated with death [23, 29].
Fourth, use of ICS was very high in children under the
age of five in Italy; this level of use certainly raises a
question about potential overprescription, especially in
children without asthma. However, a recent survey among
children 1–5 years of age showed that southern Europe had
the highest rate of wheezing symptoms (48%) compared
with northern Europe (29%), which may explain some of
the high use of ICS [4]. Although there is some evidence
supporting the effectiveness of regular inhaled cortico-
steroids in preschool wheeze [5] its use remains controversial
[7, 19]. Long-term use of steroids (inhaled and specifically
oral) might cause side effects such as temporary growth
retardation and adrenal suppression [1, 35]. Less severe but
more frequent and relevant side effects in children treated
with ICS are oropharyngeal candidiasis, dysphonia, reflex
cough, and pharyngitis [8].
Fifth, systemic corticosteroids are not the first choice of
treatment in asthma and should only be used for exacerbations.
A recent study showed that oral prednisolon and placebo
did not differ in duration of hospitalization in children with
mild to moderate wheezing associated with a viral infection
[28]. Although the high use of oral steroids in Italy is
consistent with previous study findings [2, 10, 35], it may be
slightly overestimated. Betamethasone (dispensed as capsules)
is often administered via a nebulizer, meaning that the actual
oral use will be lower than reported, unfortunately we could
not distinguish between these modes of administration.
Fixed combination therapies of an ICS+LABA are
relatively new in the treatment of childhood asthma and
their long-term safety is not well known. Use was highest
in NL, similar to a recently reported increase in use of the
fixed combination of ICS+LABA in Denmark [3]. Although
fixed combination products of ICS+LABA are only licensed
for use in children over 4 years, these drugs were also
prescribed to children <2 years in the Netherlands. We found
only one small retrospective study investigating the effect of
a fixed combination of ICS+LABA in children <4 years,
reporting a reduction in morbidity and an acceptable safety
profile [30]. So far, the safety and efficacy data of the fixed
combination of ICS+LABA in children <2 years is too scarce
to justify prescribing these drugs in young children.
In general, off-label use of asthma drugs defined as
use below the minimum age as reported in the SPCs was
low except for the fixed combination of ß2-mimetics+
anticholinergics in children <6 years in the Netherlands and
the use of SABA in children <18 months in Italy. Prescription
rates for asthma drugs in children without an asthma diagnosis
are much lower than in children diagnosed with asthma but
still surprisingly high, especially for ICS, and SABA. These
drugs may have been used to treat wheezy young children
with other respiratory conditions, such as respiratory tract
infections (e.g., bronchiolitis) or first symptoms of undiag-
nosed asthma in young preschool children, but still, overuse
cannot be excluded.
Use of asthma drugs is high, although very few long-term
safety studies are available for children. The Pediatric
Committee of the European Medicines Agency has recently
published a pediatric needs list, containing drugs that are
being used in children and where information on pharmaco-
kinetics, efficacy, and safety is urgently needed [24]. This list
includes frequently used respiratory drugs such as salbuta-
mol, fluticasone, montelukast, and many others. Although
randomized controlled trial (RCTs) are the gold standard for
efficacy assessment, safety studies are more effectively
conducted through large-scale postmarketing observational
studies [31]. Clinical trials are often small and too short for
safety assessment. Pharmacoepidemiological studies are a
valid tool for assessing safety under real-life circumstances
and often rely on secondary use of routine care data from
claims databases and medical records. This study, as well as
a previous inventory on databases with pediatric data, shows
that exposure and outcome information is available on a
large pediatric population [27, 32]. Pharmacoepidemiological
studies should be promoted to improve the safety assessment
of pediatric drugs since RCTs are hampered by methodo-
logical difficulties, especially in the pediatric subpopulation,
and consequently, results may not be prompt and sufficient
enough for safety assessment.
As for all observational research, our data has some
limitations. First of all, as we used primary care data, we
may not capture all specialist prescriptions in the UK and
the Netherlands. This will minimally influence our results
since asthma is a condition often dealt with in primary care,
and asthma drugs originally prescribed by a specialist are
often continued or prescribed by general practitioners [38].
Also, the health care provider in the studied countries differed:
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GP data from the UK and NL and family pediatrician data
from IT. However, we do not believe that this would hinder
comparability between databases as the nature of the data-
bases is the same. If there are differences between countries,
this reflects differences in primary care prescribing behavior
and not in the type of data.
Furthermore, it is not possible to diagnose asthma in
young preschool children and the diagnosis of asthma is
often made at a later age, which could lead to misclassi-
fication of the indication in young children. However, to
minimize the possibility of misclassification, we searched
the entire medical record of a child for the diagnosis of
asthma. If the diagnosis was made at a later age, the child was
counted as having asthma during the whole study period.
To conclude, our results show high use of SABA and ICS,
although not always combined, and low use of other asthma
drugs. Safety data on specific asthma drugs are needed
according to the EuropeanMedicines Agency [24]. This study
underlines the potency of healthcare databases in rapidly
providing data on pediatric drug use and possibly safety.
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